Duke University

Sentilus Holdco, LLC

Donaldson Comapny, Inc.

University of New Mexico

Other

Siemens Medical Solutions Usa, Inc.

Unm Rainforest Innovations

Sentilus, Inc.

Science & Technology Corporation &commat;t Unm

Ashutosh Chilkoti

Angus Hucknall

Gabriel P Lopez

Felipe Garcia Quiroz

Yizhi Qi

Zhongping C Yang

Plamen B Atanassov

Michael S Hershfield

Miriam Amiram

Venkata Goparaju

Nancy J Ganson

Kelli M Luginbuhl

Kelli Luginbuhl

Stefan Zauscher

Parisa Yousefpour

Daniel Joh

Lei Tang

Sonal Deshpande

Garrett Kelly

Davoud Mozhdehi

Nicholas Tang

Jayanta Bhattacharyya

Mandana Manzari

Joseph R Simon

Ali Ghoorchian

Jinho Hyun

Mareva B Fevre

Gregg E Trahey

Matthew R Dreher

Benjamin B Yellen

Kathryn R Nightingale

Levin F Nock

Aaron Franklin

Joseph Batton Andrews

Kris Cameron Wood

Wolfgang Frey

Roozbeh Abedini-Nassab

Samagya Banskota

Nick J Carroll

Caslin Gilroy

Stefan Roberts

Jason Liu

Imran Ozer

Srinath Rangarajan

Weiping Gao

Nidhi Nath

Virginia B Kraus

Lori A Setton

Helawe Betre

Described herein are albumin binding peptide drug (AlBiPeD) conjugates comprising a small molecule linked to an albumin binding domain (ABD) via a pH-sensitive linker and methods of purifying and using the same.

Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same

The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and/or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.

Genetically encoded polypeptide for affinity capture and purification of biologics

Described herein are thermally responsive polymer-therapeutic molecule conjugates comprising a therapeutic molecule conjugated to a thermally responsive polymer with an acrylate, methacrylate, acrylamide, and/or methacrylamide backbone and a plurality of oligoethylene glycol side chains.

Stimuli-responsive PEG-like polymer-based drug delivery platform

Described herein are unstructured polypeptides lacking any discernible repeat motif. Also described herein are fusion proteins including at least one of the unstructured polypeptides and at least one binding polypeptide. Further described are methods for treating a disease in a subject in need thereof. The methods may include administering to the subject an effective amount of the fusion protein.

Unstructured non-repetitive polypeptides having lcst behavior

A microarray chip imaging detector comprises a housing configured to receive a microarray chip. The detector includes a laser assembly supported by the housing and oriented at an angle relative to the microarray chip, the laser assembly configured to transmit an excitation beam along a first axis to samples on the microarray chip. The detector also includes a camera supported by the housing and positioned along a second axis, the camera configured to receive fluorescent light emitted from fluorophores in the samples on the microarray chip, the second axis oriented at an angle less than 30 degrees relative to the first axis. The housing includes a plurality of baffles positioned between the microarray chip and the camera, and a plurality of laser beamstops to receive the excitation beam reflected off the microarray chip.

Devices and methods for imaging microarray chips

Compositions and methods disclosed herein can help provide improved delivery of non-natural therapeutic nucleotides for the treatment of diseases such as cancer. An example composition includes an assembly of amphiphilic polynucleotides, where each amphiphilic polynucleotide includes an aptamer portion, a first nucleotide portion, and a second nucleotide portion.

Amphiphilic polynucleotides

Disclosed herein are compositions and methods for reducing the antigenicity of molecules. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone.

Surfaces having reduced non-specific binding and antigenicity

Disclosed herein are partially ordered polypeptides, which include a plurality of disordered domains and a plurality of structured domains. The partially ordered polypeptides may have phase transition behavior and form aggregates at, above, or below certain temperatures. Further provided are cellular scaffolds comprised of the partially ordered polypeptides.

Order and disorder as a design principle for stimuli-responsive biopolymer networks

Disclosed herein are fusion proteins including an elastin-like peptide domain, a GLP-1 receptor agonist domain attached to a N-terminal end of the ELP domain, and a FGF21 receptor agonist domain attached to the C-terminal end of the ELP domain. Also disclosed are methods of making the fusion proteins, compositions including a plurality of fusion proteins, and uses of the fusion proteins and compositions.

Dual agonist fusion proteins

Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide, where the conjugates have phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of delivering an agent, and methods of preparing the conjugates.

Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly

Nano- to microscale liquid coacervate particles are provided. The liquid coacervate particles are produced by a process including stimulating a population of liquid droplets containing one or a mixture of components to induce a phase separation point of a first component, and maintaining stimulation at the phase separation point to form a coacervate domain of the first component within each of the droplets to form the liquid coacervate particles. The self-assembled nano, meso, micro and macro liquid coacervate particles and related coated substrates can have utility in drug delivery, bioanalytical systems, controlled cell culture, tissue engineering, biomanufacturing and drug discovery.

Programmable liquid, gel and biohybrid compartments and methods of use

Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide having phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of delivering an agent, and methods of preparing the conjugates.

Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents

Growing community of inventors

Durham, NC, United States of America

Ashutosh Chilkoti